Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

The development of multiple myeloma (MM) is a complex multi-step process involving both
early and late genetic changes in the tumor cell as well as selective supportive conditions by …

Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA
in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in …

EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in
23 European countries, diagnosed in 1995–1999 and followed to December 2003. For each …

The proteasome was validated as an oncology target following the clinical success of
VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring …

Background Combinations of drug treatments based on bortezomib or lenalidomide plus
steroids have resulted in very high response rates in multiple myeloma. However, most …

We analysed data from 49 cancer registries in 18 European countries over the period 1988–
1999 to delineate time trends in cancer survival. Survival increased in Europe over the study …

Maintenance of protein homeostasis is a crucial process for the normal functioning of the
cell. The regulated degradation of proteins is primarily facilitated by the ubiquitin …

The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy;
however, CLL is still an incurable disease with resistance to therapy developing in the …

The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has
provoked considerable interest over recent years as a novel therapeutic target in cancer. A …